(Brief Background) Let me give you quick background for context
Larger randomized controlled trials are needed to confirm these findings and may help address concerns about indefinite therapy, lower healthcare costs, ease supply constraints, and broaden access to GLP-1 medications to improve public health, said the researchers.
doi: 10.1136/gut.46.5.622 161 ImeryzNYeenBCBozkurtACokunTVillanueva-PeacarrilloMLUlusoyNB
It continues, albeit at a declining rate, for much longer
It's important to note that GLP-1 receptor agonists have been associated with rare but serious digestive complications, including pancreatitis and gallbladder disease, which can affect stool appearance
That reverses a trend that saw 16 states covering the medications for obesity as of Oct